ReviewiScience2026
The DsbA-L paradox in protective and pathogenic stress adaptation.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disulfide-bond A oxidoreductase-like protein (DsbA-L), also known as glutathione S-transferase kappa 1 (GSTK1), regulates adiponectin assembly, organelle homeostasis, and cellular responses to metabolic stress. Evidence from cellular knockdown, constitutive and tissue-specific knockout models, and studies of metabolic, fibrotic, immune, and cancer contexts shows that its effects are strongly context dependent. DsbA-L can preserve metabolic homeostasis by supporting adiponectin multimerization, mitochondria-associated membrane integrity, redox control, mitophagy, and reticulophagy, yet it can also sustain profibrotic or immune-metabolic programs and show divergent effects across cancers. We propose that these observations are best understood by viewing DsbA-L as a regulator of stress adaptability whose output depends on cell identity, stress reversibility, downstream signaling, and adaptive reserve. This framework reconciles apparently conflicting findings and argues for tissue-specific modulation or downstream-effector targeting rather than indiscriminate systemic activation or inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.